Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRASS 2 / JCOG2214INT neoadjuvant chemotherapy versus surgery alone for high-risk retroperitoneal sarcoma
jRCTs031230482Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, ifosfamide and dacarbazine in retroperitoneal leiomyosarcoma (RLMS) and dedifferentiated liposarcoma (DDL) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Disease-free survival. Started Sep 2024; status: recruiting.
02
Drugs
doxorubicinifosfamidedacarbazine
03
Conditions
retroperitoneal leiomyosarcoma (RLMS)dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on jRCTs031230482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230482.